DYRK1A and diabetes mellitus: The therapeutic use of DYRK1A-mediated cell cycle regulation was recently extended to other diseases, such as diabetes and myocardial infarction, as DYRK1A inhibition was found to sustain pancreatic beta cells and cardiomyocytes growth11–16.